APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (APCVZ) said it has received approval from the U.S. Food and Drug Administration to market Chlorothiazide Sodium for Injection, USP. APP expects to launch Chlorothiazide Sodium for Injection, USP in the fourth quarter of 2009.
Chlorothiazide Sodium for Injection, USP is therapeutically equivalent to the reference-listed drug Diuril, which is marketed by Lundbeck Pharmaceuticals. APP will package Chlorothiazide Sodium for Injection, USP in single dose vials of 500 mg. APP's Chlorothiazide Sodium for Injection, USP is AP-rated, bar-coded and latex-free.
For comments and feedback: editorial@rttnews.com